Patients with Whipple's disease have a high prevalence of Helicobacter pylori infection

Eur J Intern Med. 2023 May:111:77-81. doi: 10.1016/j.ejim.2023.02.017. Epub 2023 Feb 21.

Abstract

Introduction: Whipple's disease is a rare systemic infection due to an impaired immunological response against T. whipplei in genetically predisposed individuals. Since we previously noted development of H. pylori related complications in some patients with Whipple's disease, our aim was to study the prevalence of H. pylori infection and H. pylori related disorders in Whipple's disease.

Methods: Whipple's disease patients diagnosed from Jan-2002 to Dec-2021 and two controls per patient, matched for age, gender, ethnicity and year of H. pylori testing were enrolled.

Results: 34 patients with Whipple's disease and 68 controls were enrolled. H. pylori infection (13/34 vs 8/68, p<0.01), H. pylori-related gastritis (p<0.01) and gastric atrophy (p = 0.01) were significantly more common in patients with Whipple's disease than controls. H. pylori infection and Whipple's disease were diagnosed synchronously in 6/13 patients, and during follow-up in the remaining 7. Interestingly, these last 7 patients were all on trimethoprim-sulfamethoxazole long-term therapy. Two patients developed H. pylori-related gastric malignancies during follow-up. No patients on doxycycline developed H. pylori infection.

Conclusions: H. pylori infection and related disorders are common in patients with Whipple's disease and should always be excluded both at time of diagnosis and during follow-up. These findings should be taken into account when selecting antibiotics for Whipple's disease long-term prophylaxis.

Keywords: Doxycycline; Gastric cancer; Helicobacter pylori; Peptic ulcer; Trimethoprim-sulfamethoxazole; Tropheryma whipplei; Whipple's disease.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Helicobacter Infections* / complications
  • Helicobacter Infections* / drug therapy
  • Helicobacter Infections* / epidemiology
  • Helicobacter pylori*
  • Humans
  • Prevalence
  • Whipple Disease* / complications
  • Whipple Disease* / drug therapy
  • Whipple Disease* / epidemiology

Substances

  • Anti-Bacterial Agents